Production (Stage)
NervGen Pharma Corp.
NGENF
$2.42
$0.19558.81%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.01M | 1.58M | 2.05M | 1.61M | 1.48M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.21M | 4.86M | 5.25M | 4.39M | 3.69M |
| Operating Income | -4.21M | -4.86M | -5.25M | -4.39M | -3.69M |
| Income Before Tax | -2.75M | -6.15M | -3.83M | -5.72M | -1.74M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.75M | -6.15M | -3.83M | -5.72M | -1.74M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.75M | -6.15M | -3.83M | -5.72M | -1.74M |
| EBIT | -4.21M | -4.86M | -5.25M | -4.39M | -3.69M |
| EBITDA | -4.20M | -4.85M | -5.24M | -4.37M | -3.66M |
| EPS Basic | -0.04 | -0.09 | -0.05 | -0.08 | -0.03 |
| Normalized Basic EPS | -0.02 | -0.05 | -0.03 | -0.05 | -0.02 |
| EPS Diluted | -0.04 | -0.09 | -0.05 | -0.08 | -0.03 |
| Normalized Diluted EPS | -0.02 | -0.05 | -0.03 | -0.05 | -0.02 |
| Average Basic Shares Outstanding | 70.67M | 69.99M | 70.07M | 69.95M | 60.21M |
| Average Diluted Shares Outstanding | 70.67M | 69.99M | 70.07M | 69.95M | 60.21M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |